SecBot SecBot
8-K ·Filed Nov 3, 2026

CMPS

COMPASS Pathways plc
BULLISH
Impact 6/10
Horizonweeks Processed13d 18h ago SEC0001816590-26-000078
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The NDA submission in the next two weeks is the primary near-term catalyst. Monitor for FDA acceptance and any update on the NPV review timeline. The cash runway into 2028 removes near-term financing risk.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$8.59
T+0 close · Nov 3, 2026 · via day close
Latest settled
+7.68%
T+5 · $9.25 · next T+20 in 15d
Vs SPY
+8.27%
α at T+5
Latest observation
+5.32%
T+8 · FF3 residual α
  1. T+0 · Nov 3 $8.59entry
  2. T+1 · 13d ago +0.12%α −1.54% · $8.60
  3. T+5 · 7d ago +7.68%α +8.27% · $9.25
  4. T+9 · todayOpen
  5. T+20 · in 15d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Compass Pathways reported Q3 2026 results with a GAAP net loss of $9.8M ($0.07 basic / $0.31 diluted per share), compared to a $137.7M loss in Q3 2025. The improved bottom line was driven by a $40.8M non-cash gain on warrant liabilities. The key catalyst is the imminent completion of the NDA submission for COMP360 in TRD, expected within two weeks, with potential for accelerated FDA review and commercial launch in H1 2027. Cash stood at $444M, sufficient into 2028.

Key Financial Metrics

EPS
−$0.31

Key Facts

  • Final NDA submission for COMP360 in TRD will be filed in the next two weeks, with rolling review underway.
  • National Priority Voucher could shorten FDA review to 1-2 months; White House Executive Order supports rapid DEA rescheduling.
  • Commercial launch on track for H1 2027, subject to FDA approval.
  • Cash and cash equivalents of $444M as of September 30, 2026, sufficient into 2028.
  • Net loss of $9.8M in Q3 2026 vs $137.7M in Q3 2025, primarily due to a $40.8M non-cash gain on warrant liabilities.
  • Operating loss of $56.4M in Q3 2026 vs $40.5M in Q3 2025, reflecting increased SG&A for commercial preparedness.
  • 52-week open label data from COMP005 showed added benefit from an additional COMP360 25 mg dose extending durability to one year.
  • Late-stage PTSD trial ongoing; collaboration with VA for TRD trial in veterans.

Financial Impact

Q3 2026 net loss $9.8M, operating loss $56.4M, cash $444M. No revenue.

net lossoperating expensescash position

Risk Factors

  • FDA approval is not guaranteed; COMP360 is an investigational drug with no guarantee of regulatory success.
  • DEA rescheduling is required before commercialization; timing is uncertain despite Executive Order support.
  • Commercial launch depends on FDA approval and DEA action; delays could push launch beyond H1 2027.
  • Operating losses are increasing as the company scales commercial infrastructure ahead of potential approval.
  • Warrant liabilities create significant non-cash volatility in reported net income/loss.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (24 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001816590-26-000078
Document: cmps-20261103.htm0001816590-26-000078
Document: 0001816590-26-000078-index-headers.html0001816590-26-000078
Document: 0001816590-26-000078-index.html0001816590-26-000078
Document: 0001816590-26-000078.txt0001816590-26-000078
8-K Data (Synthetic)0001816590-26-000078

Track record

6 reports on CMPS

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 3, 202613d ago 8-K Bullish 6/10 Viewing Entry $8.59 to $9.25 Now $8.27 −3.73% ▲ +7.68% +8.27% vs SPY
  2. Oct 28, 202619d ago SC 13G Neutral 4/10 Entry $12.28 to $8.60 Now $8.27 −32.65% ▼ −29.97% −29.26% vs SPY
  3. Aug 10, 202614w ago 144 Neutral 3/10 Entry $13.18 to $13.72 Now $8.27 −37.25% ▲ +4.10% +4.14% vs SPY
  4. Aug 5, 202614w ago 8-K Neutral 5/10 Entry $13.58 to $14.22 Now $8.27 −39.10% ▲ +4.71% +4.36% vs SPY
  5. Jul 7, 202618w ago 8-K Neutral 3/10 Entry $12.99 to $13.39 Now $8.27 −36.34% ▲ +3.08% +2.53% vs SPY
  6. Jun 11, 202622w ago Institutional Cluster Bullish 5/10 Entry $11.41 to $11.94 Now $8.27 −27.52% ▲ +4.64% +4.21% vs SPY
Showing 6 of 6

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026